NanoViricides Company Profile (NYSEMKT:NNVC)

About NanoViricides (NYSEMKT:NNVC)

NanoViricides logoNanoViricides, Inc. is a nano-biopharmaceutical company. The Company is a development-stage company with several drugs in various stages of development. The Company focuses on its research and clinical programs on specific anti-viral therapeutics. The Company is engaged in the application of nanomedicine technologies to the issues of viral diseases. The Company's nanoviricide technology enables direct attacks at multiple points on a virus particle. In addition, the nanoviricide technology also simultaneously enables attacking the intracellular reproduction of the virus by incorporating one or more active pharmaceutical ingredients (APIs) within the core of the nanoviricide. The nanoviricide technology is engaged in both attacking extracellular virus thereby breaking the reinfection cycle, and simultaneously disrupting intracellular production of the virus, thereby enabling complete control of a virus infection.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drug Manufacturers - Major
  • Sub-Industry: N/A
  • Symbol: NYSEMKT:NNVC
  • CUSIP: N/A
  • Web: N/A
  • Market Cap: $82.92 million
  • Outstanding Shares: 62,819,000
Average Prices:
  • 50 Day Moving Avg: $1.16
  • 200 Day Moving Avg: $1.18
  • 52 Week Range: $1.03 - $2.04
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: 33.00
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: N/A
  • Price / Sales: N/A
  • Book Value: $0.33 per share
  • Price / Book: 4.00
  • EBIDTA: ($8,620,000.00)
  • Average Volume: 66,655 shs.
  • Beta: 0.44
  • Short Ratio: 30.62

Frequently Asked Questions for NanoViricides (NYSEMKT:NNVC)

What is NanoViricides' stock symbol?

NanoViricides trades on the New York Stock Exchange (NYSE)MKT under the ticker symbol "NNVC."

How were NanoViricides' earnings last quarter?

NanoViricides Inc (NYSEMKT:NNVC) released its earnings results on Wednesday, February, 25th. The company reported ($0.03) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.05) by $0.02. The company earned $1.82 million during the quarter, compared to analysts' expectations of $1.75 million. View NanoViricides' Earnings History.

Who are some of NanoViricides' key competitors?

How do I buy NanoViricides stock?

Shares of NanoViricides can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of NanoViricides stock cost?

One share of NanoViricides stock can currently be purchased for approximately $1.32.

Analyst Ratings

Consensus Ratings for NanoViricides (NYSEMKT:NNVC) (?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A

Analysts' Ratings History for NanoViricides (NYSEMKT:NNVC)
No equities research coverage for this company has been tracked by


Earnings History for NanoViricides (NYSEMKT:NNVC)
Earnings by Quarter for NanoViricides (NYSEMKT:NNVC)
Earnings History by Quarter for NanoViricides (NYSEMKT:NNVC)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/25/2015Q215($0.05)($0.03)$1.75 million$1.82 millionViewN/AView Earnings Details
10/2/2014($0.04)($0.07)ViewN/AView Earnings Details
5/20/2014($0.04)($0.01)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for NanoViricides (NYSEMKT:NNVC)
Current Year EPS Consensus Estimate: $-0.20 EPS
Next Year EPS Consensus Estimate: $0.04 EPS


Dividend History for NanoViricides (NYSEMKT:NNVC)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for NanoViricides (NYSEMKT:NNVC)
Insider Trades by Quarter for NanoViricides (NYSEMKT:NNVC)
Insider Trades by Quarter for NanoViricides (NYSEMKT:NNVC)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
10/22/2015Milton BoniukDirectorBuy25,000$1.30$32,500.00View SEC Filing  
9/11/2015Milton BoniukDirectorBuy50,000$1.02$51,000.00View SEC Filing  
8/26/2015Milton BoniukDirectorBuy50,000$1.05$52,500.00View SEC Filing  
7/8/2015Milton BoniukDirectorBuy50,000$1.58$79,000.00View SEC Filing  
5/20/2015Milton BoniukDirectorBuy50,000$1.60$80,000.00View SEC Filing  
5/8/2015Milton BoniukDirectorBuy405,954$2.58$1,047,361.32View SEC Filing  
1/12/2015Anil DiwanMajor ShareholderBuy14,000$2.56$35,840.00View SEC Filing  
1/6/2015Milton BoniukDirectorBuy25,000$2.60$65,000.00View SEC Filing  
12/9/2014Milton BoniukDirectorBuy50,000$3.05$152,500.00View SEC Filing  
7/17/2014Milton BoniukDirectorBuy57,144$3.50$200,004.00View SEC Filing  
2/20/2014Anil DiwanMajor ShareholderBuy50,000$3.61$180,500.00View SEC Filing  
10/21/2013Anil DiwanMajor ShareholderSell142,000$5.29$751,180.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for NanoViricides (NYSEMKT:NNVC)
Latest Headlines for NanoViricides (NYSEMKT:NNVC)


This page was last updated on 5/24/2017 by Staff